Parallax Volatility Advisers, L.P. Novavax Inc Put Options Transaction History

Parallax Volatility Advisers, L.P.

14 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$3.89 - $20.97 $291,750 - $1.57 Million	75,000 Added 300.0%	100,000 $1.27 Million
Q1 2024 May 15, 2024	SELL	$3.76 - $6.02 $639,200 - $1.02 Million	-170,000 Reduced 87.18%	25,000 $119,000
Q4 2023 Feb 14, 2024	SELL	$4.8 - $7.67 $7,680 - $12,272	-1,600 Reduced 0.81%	195,000 $936,000
Q3 2023 Nov 14, 2023	BUY	$6.81 - $9.74 $1.34 Million - $1.91 Million	196,600 New	196,600 $1.42 Million
Q3 2022 Nov 14, 2022	SELL	$18.2 - $76.12 $1.67 Million - $6.96 Million	-91,500 Reduced 58.1%	66,000 $1.2 Million
Q2 2022 Aug 15, 2022	SELL	$36.28 - $75.29 $6.24 Million - $13 Million	-172,100 Reduced 52.21%	157,500 $8.1 Million
Q1 2022 May 16, 2022	SELL	$69.73 - $142.9 $20.1 Million - $41.2 Million	-288,000 Reduced 46.63%	329,600 $24.3 Million
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $8.6 Million - $13.9 Million	63,900 Added 11.54%	617,600 $88.4 Million
Q3 2021 Nov 15, 2021	BUY	$177.8 - $270.58 $98.4 Million - $150 Million	553,700 New	553,700 $115 Million
Q3 2021 Nov 15, 2021	SELL	$177.8 - $270.58 $17.6 Million - $26.8 Million	-99,200 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$121.0 - $257.67 $12 Million - $25.6 Million	99,200 New	99,200 $21.1 Million
Q1 2021 May 14, 2021	SELL	$112.98 - $319.93 $11.3 Million - $32 Million	-100,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$112.98 - $319.93 $10.9 Million - $31 Million	-96,800 Reduced 49.19%	100,000 $18.1 Million
Q4 2020 Feb 16, 2021	BUY	$78.74 - $139.5 $15.5 Million - $27.5 Million	196,800 New	196,800 $21.9 Million

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $666M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.